	Ta	TA
	Application No.	Applicant(s)
Notice of Allowability	10/018,433	BRUGIDOU ET AL.
	Examiner	Art Unit
	Mary E. Mosher, Ph.D.	1648
The MAILING DATE of this communication apperature All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIOF of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this ap or other appropriate communication IGHTS. This application is subject to	plication. If not included n will be mailed in due course. THIS
1. A This communication is responsive to 11/8/2005.		
2.  The allowed claim(s) is/are <u>1-5</u> .		
3.   Acknowledgment is made of a claim for foreign priority unal    a)   All b)   Some* c)   None of the:		
1. Certified copies of the priority documents have been received.		
2. Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached		
1)  hereto or 2)  to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s)	5 <b>- 1</b> 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
1. Notice of References Cited (PTO-892)		Patent Application (PTO-152)
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ☐ Interview Summary Paper No./Mail Da	
3. Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date	Paper No./Mail Da 08), 7. ⊠ Examiner's Amendr	nent/Comment
Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. 🛛 Examiner's Stateme	ent of Reasons for Allowance
or biological Material	9.	•
•		

Art Unit: 1648

## **REASONS FOR ALLOWANCE**

The following is an examiner's statement of reasons for allowance:

The amendment and arguments overcome the rejections of record.

The following publications are cited as of interest, in disclosing other methods of identifying and collecting proteins involved in plant virus transport:

Citovsky, V. Tobacco mosaic virus: a pioneer of cell-to-cell movement.

Philosophical transactions of the Royal Society of London. Series B, Biological sciences. Mar 29 1999, 354 (1383) p637-43.

Dorokhov et al. A novel function for a ubiquitous plant enzyme pectin methylesterase: the host-cell receptor for the tobacco mosaic virus movement protein. FEBS letters, Nov 19 1999, 461 (3) p223-8.

Jackson, D. Opening up the communication channels: Recent insights into plasmodesmal function. Current Opinion in Plant Biology 3 (5): p394-399 October, 2000.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

## **EXAMINER'S AMENDMENT**

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided

Art Unit: 1648

by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

The application has been amended as follows:

Specification pages 14 and 16 have been amended as shown on the attached sheet, to identify the brief description of the figures and to describe each figure. Support for this amendment is found at pages 50-51 and in figures 13-15 themselves.

## **Priority**

A copy of the certified application FR9907831 has been downloaded from the EPO website, and has been sent to be scanned for the file record in this application.

## Conclusion

The examiner of your application in the USPTO has changed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mary E. Mosher, Ph.D. whose telephone number is 571-272-0906. The examiner can normally be reached on Monday-Thursday and alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Housel can be reached on 571-272-0902. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1648

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

3/15/06

MARY E. MOSHER, PH.D. PRIMARY EXAMINER

Art Unit: 1648

In the specification:

The paragraph on page 14, lines 14-17 has been replaced with the following:

--Other characteristics and advantages of the invention will be given in the following examples, in which reference is made to figures I to 15. which respectively represent:

BRIEF DESCRIPTION OF THE FIGURES --

The paragraph on page 16, lines 9-11, has been replaced with the following:

-- figures 13 to 16: a chromatograph after virus injection, a SDS PAGE gel and an immunoblot with a capsid anti-protein antibody.

- figure 14: a chromatograph and a SDS PAGE gel.

- figure 15: a SDS PAGE gel and an immunoblot with a capsid anti-protein antibody.

EXAMPLES ---